Court invalidates patent on J&J’s Zytiga, but …

Here in the US, according to news reports issued late on Friday, a federal court in New Jersey invalidated the last remaining patent held by Johnson & Johnson on their formulation of abiraterone acetate, known as Zytiga, and used in the treatment of castration-resistant forms of prostate cancer. … READ MORE …

Might we see generic abiraterone acetate this year?

On Wednesday the U.S. Patent Trial and Appeal Board invalidated the last remaining patent on abiraterone acetate (Zytiga), making it possible that generic forms of abiraterone acetate would be available in 2018 (at least in the US). … READ MORE …

Pfizer’s patent for Viagra expires today … in Europe

According to a story on the FiercePharma web site, the patent for sildenafil (Viagra) will expire today in Europe. This ought to lead to a significant drop in the price for a very popular drug as generic equivalents rapidly come available. Here in the USA, however, Pfizer has managed to extend the patent for Viagra to 2020 (through litigation).

 

SCOTUS rules on patentability of human genes

Earlier today, the Supreme Court of the United States (SCOTUS) ruled against Myriad Genetics in an important gene patenting case that we have discussed frequently on this site in the past couple of years. … READ MORE …

Can a company patent a human gene? The showdown comes on Monday!

Next Monday, after conflicting rulings in other courts over the past 4 years, the case of Association for Molecular Pathology v. Myriad Genetics will be fought out before the Supreme Court of the United States (SCOTUS). At stake is the complex issue of exactly what is patentable related to the isolation and use of portions of the human genome (and other, related issues). … READ MORE …

Gene patenting issue to be addressed by Supreme Court

As regular readers may remember, The “New” Prostate Cancer InfoLink has been keeping an eye on the court case known as the Association for Molecular Pathology v. Myriad Genetics, Inc. The case relates to the rights of the biotechnology industry (or indeed any other organization or individual) to hold patents on human genes and/or their scientific uses. … READ MORE …

Why would anyone develop new drugs if international patent law can just be ignored?

There are two ways to look at a ruling issued yesterday by the Indian controller general of patents, designs and trademarks: it can either be seen as a major victory for patients who had no prior hope of treatment with a highly effective anticancer agent because of its cost … or it can be seen as an international setback to the entire concept of patent and intellectual property law. … READ MORE …